Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
10.21
+0.75 (7.93%)
At close: Jun 26, 2026, 4:00 PM EDT
10.18
-0.03 (-0.29%)
After-hours: Jun 26, 2026, 7:42 PM EDT
Karyopharm Therapeutics Employees
Karyopharm Therapeutics had 228 employees as of December 31, 2025. The number of employees decreased by 51 or -18.28% compared to the previous year.
Employees
228
Change (1Y)
-51
Growth (1Y)
-18.28%
Revenue / Employee
$662,798
Profits / Employee
-$855,127
Market Cap
231.39M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Fate Therapeutics | 161 |
| Codexis | 146 |
| Voyager Therapeutics | 141 |
| Alector | 103 |
| Immunic | 95 |
| Keros Therapeutics | 87 |
| Protara Therapeutics | 46 |
| Whitehawk Therapeutics | 29 |
KPTI News
- 24 days ago - Karyopharm Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 24 days ago - Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 - PRNewsWire
- 25 days ago - Karyopharm Therapeutics Transcript: Study result - Transcripts
- 25 days ago - Karyopharm Therapeutics Press release: Study result - Filings
- 25 days ago - Karyopharm Therapeutics Slides: Study result - Filings
- 26 days ago - Karyopharm says Phase 3 SENTRY trial selected for presentation at EHA 2026 - TheFly
- 26 days ago - Karyopharm’s selinexor combination shows efficacy in myelofibrosis - TheFly
- 26 days ago - Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 - PRNewsWire